Fluicell ABOSTO:FLUI +2.72%54 PS Ratio is 3.94 as of Jul. 05, 2026, which is 81% below its 10-year median of 20.77. GuruFocus rates OSTO:FLUI with a GF Score™ of 54/100 and a GF Value™ of kr34.52 (Fairly Valued). The stock has 4 warning signs investors should review. Among 931 Biotechnology companies, Fluicell AB ranks better than 72.82% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Fluicell AB's share price is kr34.00.
Fluicell AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr8.64. Hence, Fluicell AB's PS Ratio for today is 3.94.
The historical rank and industry rank for Fluicell AB's PS Ratio or its related term are showing as below:
OSTO:FLUI'
s PS Ratio Range Over the Past 10 Years
Min: 0.46 Med: 20.77 Max: 150.36
Current: 3.94
During the past 11 years, Fluicell AB's highest PS Ratio was 150.36. The lowest was 0.46. And the median was 20.77.
OSTO:FLUI's PS Ratio is ranked better than 72.82% of 931
companies
in the Biotechnology industry
Industry Median: 9.93
vs OSTO:FLUI: 3.94
Fluicell AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Fluicell AB was 485.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -26.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -38.00% per year.
During the past 11 years, Fluicell AB's highest 3-Year average Revenue per Share Growth Rate was 30.40% per year. The lowest was -55.90% per year. And the median was -23.50% per year.
Back to Basics: PS Ratio
Fluicell AB (OSTO:FLUI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Fluicell AB PS Ratio Related Terms
Fluicell AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Fluicell AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Fluicell AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Fluicell AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Fluicell AB's Share Price of today is kr34.00. Fluicell AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Fluicell AB (OSTO:FLUI) has a PS Ratio of 3.94 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fluicell AB and its competitors. This is 81% below median its historical median of 20.77. Over the past decade, Fluicell AB's PS Ratio has ranged from 0.46 to 150.36. According to the industry distribution chart, Fluicell AB ranks #253 out of 931 companies in the Biotechnology industry, placing it in the top 27.2%.
Is Fluicell AB's PS Ratio too high?
Fluicell AB's current PS Ratio of 3.94 is 81% below median its 10-year median of 20.77. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 150.36. The Biotechnology industry median PS Ratio is 9.93. Fluicell AB's value of 3.94 is 60.3% below this industry median. Based on the distribution chart, Fluicell AB ranks #253 out of 931 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #253 out of 931 companies for PS Ratio. This puts Fluicell AB in the upper half of its industry. The industry median PS Ratio is 9.93. Fluicell AB's value of 3.94 is 60.3% below this benchmark. Historically, Fluicell AB's own PS Ratio has ranged from 0.46 to 150.36 over the past decade. While the company's 10-year median is 20.77 vs. the industry median of 9.93, Fluicell AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.93, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current PS Ratio of 3.94 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current PS Ratio is 3.94, which is 81% below median its own 10-year median of 20.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr34.52, compared to a current price of kr34.00 — trading 1.5% below its estimated fair value. The current PS Ratio is 3.94, which is 81% below median its 10-year median of 20.77 and 60.3% below the Biotechnology industry median of 9.93. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current PS Ratio is 3.94 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr34.00 is trading 1.5% below its estimated GF Value™ of kr34.52.
GuruFocus considers Fluicell AB to be Fairly Valued.
Key valuation signals for OSTO:FLUI:
PS Ratio: 3.94 (81% below median its 10-year median of 20.77)
GF Value™: kr34.52 vs. price of kr34.00 (1.5% below fair value)
Industry Position: 60.3% below the Biotechnology median (#253 of 931)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for OSTO:FLUI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
